Advancements in Immunology and Immunotherapy for Breast Cancer

104.8K

views

118

authors

16

articles

Advancements in Immunology and Immunotherapy for Breast Cancer

104.8K

views

118

authors

16

articles

Editorial

09 August 2022

Editorial: Advancements in immunology and immunotherapy for breast cancer

Tomoharu Sugie

,

Roberto Salgado

and

Lawrence Fong

2,202 views

1 citations

Editors

3

Kansai Medical University Hospital

Roberto Salgado

University of California, San Francisco

Impact

About

The success of immune checkpoint inhibitors (ICIs) across the organs demonstrates the existence of anti-cancer immunity in patients with malignant tumors. Breast cancer was traditionally thought to be poorly immunogenic compared to highly immunogenic (‘inflamed’) cancers, including malignant melanoma and non-small cell lung carcinoma. However, PD-1/ PD-L1 targeted therapies can improve the clinical outcomes of metastatic triple-negative breast cancer (TNBC) and anti-tumor response in early TNBC respectively.

As the efficacy of immuno-oncology (IO) monotherapy is limited, the development of IO is focused on the combination of ICIs and chemotherapy, targeted drugs, or radiation. However, the best partner for immune checkpoint inhibitors and optimal treatment sequence is still unknown. A precise understanding of immunobiology and the development of tumor-intrinsic and extrinsic biomarkers is required to maximize the clinical benefits of immunotherapy in patients with breast cancer.

In this Research Topic, we will focus on the basis of cancer immunity and current status, and future perspectives of IO for breast cancer. We welcome Mini-reviews, Reviews, and Original Articles for basic immunology and preclinical translational research in breast cancer.

The success of immune checkpoint inhibitors (ICIs) across the organs demonstrates the existence of anti-cancer immunity in patients with malignant tumors. Breast cancer was traditionally thought to be poorly immunogenic compared to highly immunogenic (‘inflamed’) cancers, including malignant melanoma and non-small cell lung carcinoma. However, PD-1/ PD-L1 targeted therapies can improve the clinical outcomes of metastatic triple-negative breast cancer (TNBC) and anti-tumor response in early TNBC respectively.

As the efficacy of immuno-oncology (IO) monotherapy is limited, the development of IO is focused on the combination of ICIs and chemotherapy, targeted drugs, or radiation. However, the best partner for immune checkpoint inhibitors and optimal treatment sequence is still unknown. A precise understanding of immunobiology and the development of tumor-intrinsic and extrinsic biomarkers is required to maximize the clinical benefits of immunotherapy in patients with breast cancer.

In this Research Topic, we will focus on the basis of cancer immunity and current status, and future perspectives of IO for breast cancer. We welcome Mini-reviews, Reviews, and Original Articles for basic immunology and preclinical translational research in breast cancer.

Download ebook

Share

Editors

Kansai Medical University Hospital

Roberto Salgado

University of California, San Francisco

Impact

104,826 Total views

77,843 Article views

25,750 Article downloads

1,233 Topic views

Published In

Journal Thumbnail

Frontiers in Oncology

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Suggest a topic